O.V. Morov1,2, R.Sh. Khasanov2
1Republican Clinical Oncology Dispensary of Ministry of Healthcare of Tatarstan Republic named after prof. M.Z. Sigal, Kazan
2Kazan State Medical Academy ― Branch Campus of the FSBEI FPE RMACPE MOH Russia, Kazan Моров Олег Витальевич ― кандидат медицинских наук, врач-радиотерапевт, заведующий отделением дневного стационара №2 ГАУЗ «Республиканский клинический онкологический диспансер МЗ Республики Татарстан им. проф. М.З. Сигала», доцент кафедры онкологии, радиологии и паллиативной медицины Казанской государственной медицинской академии — филиала ФГБОУ ДПО РМАНПО МЗ РФ
Morov Oleg V. ― Cand. of Sci. (Med.), radiation oncologist, head of day hospital department №2 of the Republican Clinical Oncology Dispensary of Ministry of Healthcare of Tatarstan Republic named after prof. M.Z. Sigal; associate professor of the department of oncology, radiology and palliative medicine of the Kazan State Medical Academy ― Branch Campus of the FSBEI FPE RMACPE MOH Russia
29 Sibirskiy Trakt, Kazan, 420029, Russian Federation, tel.: (843) 233-86-31, +7-987-269-33-96, e-mail: morvaks@mail.ru, ORCID ID: 0009-0008-9241-6703
Abstract
The purple of the study was to study the prevalence and structure of primary multiple malignant neoplasms in patients diagnosed with prostate cancer, and to assess their impact on survival.
Material and methods. A retrospective analysis of data from patients diagnosed with localized or locally advanced prostate cancer who received radical specialized treatment in the oncological (surgical) and radiotherapeutic departments of the Republican Clinical Oncology Dispensary of Ministry of Healthcare of Tatarstan Republic named after prof. M.Z. Sigal (Kazan) for the period from 2011 to 2020.
Results. The study included 5266 patients. The median age was 66 years. 66,7% of patients received radiotherapy, 33,3% of patients received prostatectomy. The median follow-up time was 6,9 years. The median overall survival was 12,7 years. 859 patients (16,3%) were diagnosed with 967 primary multiple malignant neoplasms, 276 (28,5%) of which were detected before prostate cancer, 72 (7,5%) were diagnosed synchronously, 619 (64%) were metachronous after prostate cancer. The most common second primary tumors were nonmelanoma skin cancer, colorectal cancer, lung cancer, gastric cancer, and urinary tract tumors. The median survival time from the moment of prostate cancer diagnosis in the group where there were no primary multiple malignancies was 13,5 years (95% CI: 12.9-16.1). In the group of patients who, in addition to prostate cancer, were diagnosed with a second primary malignancy in their lifetime, the median survival time was 9,4 years (95% CI: 8.6-10.1). Detection of primary multiple malignant neoplasms increased the risk of death from any cause by 1,834 times.
Conclusions. In patients diagnosed with prostate cancer, multiple primary malignancies are quite common. This problem requires further study in order to identify additional risk factors for second primary tumors in order to develop measures for their prevention, timely detection and treatment.
Key words: prostate cancer, primary multiple malignant neoplasms, metachronous tumors, incidence, survival, risk factors, hazard ratio.